Victoria Nachar

441 total citations
27 papers, 138 citations indexed

About

Victoria Nachar is a scholar working on Oncology, Hematology and Pathology and Forensic Medicine. According to data from OpenAlex, Victoria Nachar has authored 27 papers receiving a total of 138 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 10 papers in Hematology and 8 papers in Pathology and Forensic Medicine. Recurrent topics in Victoria Nachar's work include Lymphoma Diagnosis and Treatment (8 papers), Multiple Myeloma Research and Treatments (5 papers) and Acute Myeloid Leukemia Research (4 papers). Victoria Nachar is often cited by papers focused on Lymphoma Diagnosis and Treatment (8 papers), Multiple Myeloma Research and Treatments (5 papers) and Acute Myeloid Leukemia Research (4 papers). Victoria Nachar collaborates with scholars based in United States, Australia and New Zealand. Victoria Nachar's co-authors include Anthony J. Perissinotti, Bernard L. Marini, Anna M. Brown, Shannon Hough, Tycel Phillips, Dale L. Bixby, Renwick C. J. Dobson, André O. Hudson, Katherine A. Donovan and Matthew J. Pianko and has published in prestigious journals such as Blood, Frontiers in Microbiology and Critical Reviews in Oncology/Hematology.

In The Last Decade

Victoria Nachar

25 papers receiving 137 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Victoria Nachar United States 8 64 49 27 24 23 27 138
Omotayo Fasan United States 6 55 0.9× 49 1.0× 29 1.1× 17 0.7× 14 0.6× 15 112
Machiko Kusuda Japan 8 56 0.9× 82 1.7× 20 0.7× 13 0.5× 22 1.0× 38 152
Tara Cochrane Australia 7 52 0.8× 56 1.1× 52 1.9× 34 1.4× 54 2.3× 36 156
Je Jung Lee South Korea 8 49 0.8× 111 2.3× 19 0.7× 34 1.4× 23 1.0× 28 203
Shawnda Tench United States 7 61 1.0× 92 1.9× 40 1.5× 14 0.6× 24 1.0× 17 150
Malgorzata McMasters United States 7 35 0.5× 59 1.2× 10 0.4× 27 1.1× 17 0.7× 18 120
Sara Varea Spain 7 51 0.8× 30 0.6× 14 0.5× 70 2.9× 16 0.7× 13 176
Tomasz Ociepa Poland 8 32 0.5× 43 0.9× 12 0.4× 25 1.0× 7 0.3× 28 136
Srinivas Devarakonda United States 9 94 1.5× 103 2.1× 13 0.5× 73 3.0× 17 0.7× 54 234
Patrick Harrington United Kingdom 8 30 0.5× 70 1.4× 7 0.3× 20 0.8× 67 2.9× 28 168

Countries citing papers authored by Victoria Nachar

Since Specialization
Citations

This map shows the geographic impact of Victoria Nachar's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Victoria Nachar with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Victoria Nachar more than expected).

Fields of papers citing papers by Victoria Nachar

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Victoria Nachar. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Victoria Nachar. The network helps show where Victoria Nachar may publish in the future.

Co-authorship network of co-authors of Victoria Nachar

This figure shows the co-authorship network connecting the top 25 collaborators of Victoria Nachar. A scholar is included among the top collaborators of Victoria Nachar based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Victoria Nachar. Victoria Nachar is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Davis, James, Donald C. Moore, Charlotte B Wagner, et al.. (2024). Dexamethasone for the Management of CRS Related to Teclistamab in Patients with Relapsed/Refractory Multiple Myeloma. Blood. 144(Supplement 1). 2382–2382. 1 indexed citations
2.
Mahmoudjafari, Zahra, et al.. (2024). Seamless Navigation of Bispecific Therapies: Optimizing Management and Outpatient Access With a Focus on Coordination. Journal of the Advanced Practitioner in Oncology. 15(8). 1–16. 2 indexed citations
3.
Yang, Xi, Victoria Nachar, Shannon A. Carty, et al.. (2024). Risk Factors for Cytokine Release Syndrome in Patients Receiving Bispecific Antibodies for B-Cell Lymphoma: A Single-Center, Retrospective Cohort Study. Blood. 144(Supplement 1). 4477–4477. 2 indexed citations
4.
Pianko, Matthew J., et al.. (2024). Administration of teclistamab in four patients with multiple myeloma requiring hemodialysis. Journal of Oncology Pharmacy Practice. 30(6). 1089–1095. 5 indexed citations
5.
Nachar, Victoria, Lydia L. Benitez, Shannon A. Carty, et al.. (2024). Risk Factors for Severe Infection in Patients Receiving Bispecific Antibody Therapies for Lymphoma. Blood. 144(Supplement 1). 3105–3105. 1 indexed citations
6.
Phillips, Tycel, David A. Bond, Malathi Kandarpa, et al.. (2023). Adding venetoclax to lenalidomide and rituximab is safe and effective in patients with untreated mantle cell lymphoma. Blood Advances. 7(16). 4518–4527. 7 indexed citations
7.
8.
9.
Nachar, Victoria, et al.. (2021). Implementation and outcomes of a pharmacist-led collaborative drug therapy management program for oncology symptom management. Supportive Care in Cancer. 29(11). 6505–6510. 11 indexed citations
10.
11.
Schaefer, Jordan K., Amro Elshoury, Victoria Nachar, Michael B. Streiff, & Ming Y. Lim. (2021). How to Choose An Appropriate Anticoagulant for Cancer-Associated Thrombosis.. PubMed. 19(10). 1203–1210. 7 indexed citations
12.
Perissinotti, Anthony J., Bernard L. Marini, Anna M. Brown, et al.. (2021). Late-onset complications with bendamustine versus CHOP or CVP based chemoimmunotherapy in indolent Non-Hodgkin’s lymphoma. Leukemia & lymphoma. 62(13). 3138–3146. 3 indexed citations
13.
Benitez, Lydia L., et al.. (2020). Evaluating the Role of Novel Oncology Agents: Oncology Stewardship in Relapsed/Refractory Diffuse Large B-Cell Lymphoma. Clinical Lymphoma Myeloma & Leukemia. 21(5). 295–308. 2 indexed citations
14.
Marini, Bernard L., et al.. (2020). Contemporary treatment options for a classical disease: Advanced Hodgkin lymphoma. Critical Reviews in Oncology/Hematology. 148. 102897–102897. 1 indexed citations
15.
Nachar, Victoria, et al.. (2019). Successful rechallenge of rituximab following severe rituximab-induced acute thrombocytopenia in a patient with splenic marginal zone lymphoma. Journal of Oncology Pharmacy Practice. 26(5). 1248–1253. 3 indexed citations
16.
Nachar, Victoria, et al.. (2019). Clinician Report of Oral Oncolytic Symptoms and Adherence Obtained via a Patient-Reported Outcome Measure (PROM). JCO Clinical Cancer Informatics. 3(3). 1–6. 5 indexed citations
17.
Perissinotti, Anthony J., Victoria Nachar, Dale L. Bixby, et al.. (2018). The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia. Leukemia Research. 70. 91–96. 18 indexed citations
18.
Marini, Bernard L., et al.. (2017). Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG. Annals of Hematology. 97(4). 573–584. 6 indexed citations
19.
20.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Omotayo Fasan Breakdown of academic impact, for papers by Machiko Kusuda Breakdown of academic impact, for papers by Tara Cochrane Breakdown of academic impact, for papers by Je Jung Lee Breakdown of academic impact, for papers by Shawnda Tench Breakdown of academic impact, for papers by Malgorzata McMasters Breakdown of academic impact, for papers by Sara Varea Breakdown of academic impact, for papers by Tomasz Ociepa Breakdown of academic impact, for papers by Srinivas Devarakonda Breakdown of academic impact, for papers by Patrick Harrington
Rankless by CCL
2026